Previous 10 | Next 10 |
Presented pre-clinical data at American Association for Cancer Research (AACR 2022), demonstrating GTB-5550 (cam16-IL15-camB7H3) Tri-specific Killer Engager (TriKE ® ) driving NK cell activation and ADCC against head and neck squamous cell carcinomas GT Biopharma to partici...
BRISBANE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), an immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary tri-specific natural killer (NK) cell engager, TriKE ® protein biologic technology platf...
- Ongoing experiments will evaluate the functionality and efficacy of the B7H3 TriKE in vivo - Future studies will also involve assessments of the B7H3 TriKE efficacy in the HNSCC tumor microenvironment BRISBANE, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (&...
GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update PR Newswire Presented novel TriKE ® pre-clinical data driving NK cell immunotherapy against non-small cell lung cancer (NSCLC) in the hypoxic solid tumor mic...
GT Biopharma Presents TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting PR Newswire - GTB-5550 TriKE significantly enhances NK cell mediated killing of myeloma cells, even in the relatively low B7-H3...
GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE® Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022 - Results suggest that mesothelin-targeted TriKE can work alongside current standard of care and prov...
GT Biopharma (NASDAQ: GTBP) is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary TriKE(R) NK cell engager platform. The company’s TriKE(R) platform is designed to harness and e...
GT Biopharma to Participate In-Person at 34th Annual ROTH Conference, March 13-15, 2022 PR Newswire BRISBANE, Calif. , March 3, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing inn...
GT Biopharma to Present Pre-Clinical Data at Upcoming Medical Conferences PR Newswire BRISBANE, Calif. , Feb. 24, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based ...
GT Biopharma (NASDAQ:GTBP), a clinical-stage immunooncology company, has named Manu Ohri as its Chief Financial Officer (CFO) with immediate effect. Ohri has over 25 years of management, finance and public accounting experience and has served as CFO for multiple public companies. He was previ...
News, Short Squeeze, Breakout and More Instantly...
GTB-3650 Phase 1 trial initiation expected in H2 2024; initial clinical data expected in H1 2025 GTB-5550 TriKE ® IND submission for treatment of B7H3 positive solid tumors expected in Q1 2025 GTB-5550 Phase 1 dose escalation basket trial initiation expected in 20...
BRISBANE, CALIFORNIA, May 21, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), today announced that it has entered into a definitive securities purchase agreements for the purchase and sale of 740,000 shares of the Company’s common stock at a purcha...
A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 16.4% to $0.199 on volume of 720,586,242 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 74.8% to $1.8 on volume of 682,362,254 shares Pineapple Energy Inc. (PEGY) rose 80.3% to $0.1...